Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX -9.09% EV-to-OCF is -28.54 as of Aug. 02, 2026. The stock has 7 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 91.21% on this metric.
The historical rank and industry rank for Lumos Diagnostics Holdings's EV-to-OCF or its related term are showing as below:
ASX:LDX'
s EV-to-OCF Range Over the Past 10 Years
Min: -31.24 Med: -1.24 Max: 17.92
Current: -31.24
During the past 4 years, the highest EV-to-OCF of Lumos Diagnostics Holdings was 17.92. The lowest was -31.24. And the median was -1.24.
ASX:LDX's EV-to-OCF is ranked better than 91.21% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.9
vs ASX:LDX: -31.24
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lumos Diagnostics Holdings's PE Ratio (TTM) for today is calculated as:
Lumos Diagnostics Holdings's share price for today is A$0.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumos Diagnostics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lumos Diagnostics Holdings EV-to-OCF Related Terms
Lumos Diagnostics Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lumos Diagnostics Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's EV-to-OCF falls into.
Lumos Diagnostics Holdings's current Enterprise Value is A$99.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumos Diagnostics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a EV-to-OCF of -28.54 as of Aug. 02, 2026. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #75 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 8.8%.
Is Lumos Diagnostics Holdings' EV-to-OCF too high?
Lumos Diagnostics Holdings' current EV-to-OCF is -28.54. Based on the distribution chart, Lumos Diagnostics Holdings ranks #75 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Lumos Diagnostics Holdings' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #75 out of 853 companies for EV-to-OCF. This places Lumos Diagnostics Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.90, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current EV-to-OCF is -28.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.10 — trading 400% above its estimated fair value. The current EV-to-OCF is -28.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current EV-to-OCF is -28.54 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
